院外感染性肺炎(Community Acquired Pneumonia)の治療薬パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Community Acquired Pneumonia Overview 6
Therapeutics Development 7
Pipeline Products for Community Acquired Pneumonia – Overview 7
Pipeline Products for Community Acquired Pneumonia – Comparative Analysis 8
Community Acquired Pneumonia – Therapeutics under Development by Companies 9
Community Acquired Pneumonia – Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Community Acquired Pneumonia – Products under Development by Companies 14
Community Acquired Pneumonia – Companies Involved in Therapeutics Development 15
Actavis plc 15
AstraZeneca PLC 16
Biotest AG 17
C10 Pharma AS 18
Kyorin Pharmaceutical Co., Ltd. 19
Paratek Pharmaceuticals, Inc. 20
TaiGen Biotechnology Co., Ltd. 21
Takeda Pharmaceutical Company Limited 22
Community Acquired Pneumonia – Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
BT-086 – Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
C-10 – Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
ceftaroline fosamil – Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
dalbavancin – Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
KRPAM-1977X – Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
nemonoxacin – Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
omadacycline – Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Small Molecules for SSTI and CAP Infections – Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
ticagrelor – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Community Acquired Pneumonia – Recent Pipeline Updates 50
Community Acquired Pneumonia – Dormant Projects 65
Community Acquired Pneumonia – Discontinued Products 66
Community Acquired Pneumonia – Product Development Milestones 67
Featured News & Press Releases 67
Oct 03, 2014: FDA Grants Durata Therapeutics a Special Protocol Agreement for Its Phase 3 Study of DALVANCE in Hospitalized Community-Acquired Pneumonia 67
Sep 11, 2013: New Antibiotic Shows Promise for Treating MRSA Pneumonia 67
May 16, 2013: TaiGen Biotechnology Submits New Drug Application For Nemonoxacin In Taiwan And China 68
Aug 28, 2012: European Commission Approves Zinforo To Treat Skin Infections Or Community Acquired Pneumonia 69
Jun 22, 2012: CHPM Adopts Positive Opinion For Zinforo For Treatment Of Complicated Skin And Soft Tissue Infections 69
Appendix 71
Methodology 71
Coverage 71
Secondary Research 71
Primary Research 71
Expert Panel Validation 71
Contact Us 72
Disclaimer 72